Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease

To assess the influence of therapy crossovers on treatment comparisons and mortality at 5 years in patients with ischemic heart disease and heart failure randomly assigned to medical therapy alone (MED) or to MED and coronary artery bypass graft (CABG) surgery in the Surgical Treatment for Ischemic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation. Heart failure 2013-05, Vol.6 (3), p.443-450
Hauptverfasser: Doenst, Torsten, Cleland, John G F, Rouleau, Jean L, She, Lilin, Wos, Stanislaw, Ohman, E Magnus, Krzeminska-Pakula, Maria, Airan, Balram, Jones, Robert H, Siepe, Matthias, Sopko, George, Velazquez, Eric J, Racine, Normand, Gullestad, Lars, Filgueira, Jose Luis, Lee, Kerry L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 450
container_issue 3
container_start_page 443
container_title Circulation. Heart failure
container_volume 6
creator Doenst, Torsten
Cleland, John G F
Rouleau, Jean L
She, Lilin
Wos, Stanislaw
Ohman, E Magnus
Krzeminska-Pakula, Maria
Airan, Balram
Jones, Robert H
Siepe, Matthias
Sopko, George
Velazquez, Eric J
Racine, Normand
Gullestad, Lars
Filgueira, Jose Luis
Lee, Kerry L
description To assess the influence of therapy crossovers on treatment comparisons and mortality at 5 years in patients with ischemic heart disease and heart failure randomly assigned to medical therapy alone (MED) or to MED and coronary artery bypass graft (CABG) surgery in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. The influence of early crossover (within the first year after randomization) on 5-year mortality was assessed using time-dependent multivariable Cox models. CABG was performed in 65/602 patients (10.8%) assigned to MED, and 55/610 patients (9.0%) assigned to CABG received MED only. Common reasons for crossover from MED to CABG were progressive symptoms or acute decompensation. MED-assigned patients who underwent CABG had lower 5-year mortality than those who received MED only (25% vs 42%; hazard ratio, 0.50; 95% confidence interval, 0.30-0.85; P=0.008).The main reason for crossover from CABG to MED was patient/family decision. Five patients did not undergo their assigned CABG within a year but died before receiving surgery without status change. They were deemed crossover to MED. The CABG-to-MED crossover population had higher 5-year mortality compared with those treated with CABG per-protocol (59% vs 33%; hazard ratio, 2.01; 95% confidence interval, 1.36-2.96; P
doi_str_mv 10.1161/CIRCHEARTFAILURE.112.000130
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3721746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1354790485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-5975b3a764fe3088c58cac392095bc8d1401dbe57119ea46990963a66e07fdd3</originalsourceid><addsrcrecordid>eNpdUdFqGzEQFKWhSdP-QhH0pS9OpNPp7kShYIzTGAwB4z6LtW6vVrmTXEnn4HxGv7hKnZokT7vszswOO4R85uyK84pfzxar2e18ulrfTBfLH6t5nhZXjDEu2BtywVXJJ6JQ9dtT36hz8j7GX4xVhZTqHTkvhOSyqOUF-bNwXT-iM0h9R03wMfo9BuodHXxI0Nt0oNZRoAFc6wf7gC2NaWwPj_iAe4hm7CHYB0g2kzJ0lzt0KdJ7m7Y0HmLyvTV0ixAS7cD2Y0CaxajxwTsIB5oXmEtrI0LED-Ssgz7ix6d6SdY38_XsdrK8-76YTZcTUxYqTaSq5UZAXZUdCtY0RjYGjFAFU3JjmpaXjLcblDXnCqGslGKqElBVyOqubcUl-XaU3Y2bAVuTLQfo9S7YIXvSHqx-uXF2q3_6vRZ1weuyygJfngSC_z1iTHqw0WDfg0M_Rs2FLGvFykZm6Ncj9N-DA3anM5zpx1D161DztNDHUDP703OnJ-7_FMVfFiylBw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1354790485</pqid></control><display><type>article</type><title>Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Doenst, Torsten ; Cleland, John G F ; Rouleau, Jean L ; She, Lilin ; Wos, Stanislaw ; Ohman, E Magnus ; Krzeminska-Pakula, Maria ; Airan, Balram ; Jones, Robert H ; Siepe, Matthias ; Sopko, George ; Velazquez, Eric J ; Racine, Normand ; Gullestad, Lars ; Filgueira, Jose Luis ; Lee, Kerry L</creator><creatorcontrib>Doenst, Torsten ; Cleland, John G F ; Rouleau, Jean L ; She, Lilin ; Wos, Stanislaw ; Ohman, E Magnus ; Krzeminska-Pakula, Maria ; Airan, Balram ; Jones, Robert H ; Siepe, Matthias ; Sopko, George ; Velazquez, Eric J ; Racine, Normand ; Gullestad, Lars ; Filgueira, Jose Luis ; Lee, Kerry L ; STICH Investigators</creatorcontrib><description>To assess the influence of therapy crossovers on treatment comparisons and mortality at 5 years in patients with ischemic heart disease and heart failure randomly assigned to medical therapy alone (MED) or to MED and coronary artery bypass graft (CABG) surgery in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. The influence of early crossover (within the first year after randomization) on 5-year mortality was assessed using time-dependent multivariable Cox models. CABG was performed in 65/602 patients (10.8%) assigned to MED, and 55/610 patients (9.0%) assigned to CABG received MED only. Common reasons for crossover from MED to CABG were progressive symptoms or acute decompensation. MED-assigned patients who underwent CABG had lower 5-year mortality than those who received MED only (25% vs 42%; hazard ratio, 0.50; 95% confidence interval, 0.30-0.85; P=0.008).The main reason for crossover from CABG to MED was patient/family decision. Five patients did not undergo their assigned CABG within a year but died before receiving surgery without status change. They were deemed crossover to MED. The CABG-to-MED crossover population had higher 5-year mortality compared with those treated with CABG per-protocol (59% vs 33%; hazard ratio, 2.01; 95% confidence interval, 1.36-2.96; P&lt;0.001). CABG was associated with lower mortality compared with MED in per-protocol and several time-dependent analyses (all P&lt;0.05). CABG reduced mortality in both the per-protocol and crossover STICH patient populations. Crossover from assigned therapy, therefore, diminished the impact of CABG on survival in STICH when analyzed by intention to treat. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.</description><identifier>ISSN: 1941-3289</identifier><identifier>EISSN: 1941-3297</identifier><identifier>DOI: 10.1161/CIRCHEARTFAILURE.112.000130</identifier><identifier>PMID: 23515275</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Comorbidity ; Coronary Artery Bypass - mortality ; Coronary Artery Disease - drug therapy ; Coronary Artery Disease - mortality ; Coronary Artery Disease - surgery ; Coronary Artery Disease - therapy ; Cross-Over Studies ; Disease Progression ; Female ; Heart Failure, Systolic - mortality ; Humans ; Male ; Middle Aged</subject><ispartof>Circulation. Heart failure, 2013-05, Vol.6 (3), p.443-450</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-5975b3a764fe3088c58cac392095bc8d1401dbe57119ea46990963a66e07fdd3</citedby><cites>FETCH-LOGICAL-c429t-5975b3a764fe3088c58cac392095bc8d1401dbe57119ea46990963a66e07fdd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3674,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23515275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doenst, Torsten</creatorcontrib><creatorcontrib>Cleland, John G F</creatorcontrib><creatorcontrib>Rouleau, Jean L</creatorcontrib><creatorcontrib>She, Lilin</creatorcontrib><creatorcontrib>Wos, Stanislaw</creatorcontrib><creatorcontrib>Ohman, E Magnus</creatorcontrib><creatorcontrib>Krzeminska-Pakula, Maria</creatorcontrib><creatorcontrib>Airan, Balram</creatorcontrib><creatorcontrib>Jones, Robert H</creatorcontrib><creatorcontrib>Siepe, Matthias</creatorcontrib><creatorcontrib>Sopko, George</creatorcontrib><creatorcontrib>Velazquez, Eric J</creatorcontrib><creatorcontrib>Racine, Normand</creatorcontrib><creatorcontrib>Gullestad, Lars</creatorcontrib><creatorcontrib>Filgueira, Jose Luis</creatorcontrib><creatorcontrib>Lee, Kerry L</creatorcontrib><creatorcontrib>STICH Investigators</creatorcontrib><title>Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease</title><title>Circulation. Heart failure</title><addtitle>Circ Heart Fail</addtitle><description>To assess the influence of therapy crossovers on treatment comparisons and mortality at 5 years in patients with ischemic heart disease and heart failure randomly assigned to medical therapy alone (MED) or to MED and coronary artery bypass graft (CABG) surgery in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. The influence of early crossover (within the first year after randomization) on 5-year mortality was assessed using time-dependent multivariable Cox models. CABG was performed in 65/602 patients (10.8%) assigned to MED, and 55/610 patients (9.0%) assigned to CABG received MED only. Common reasons for crossover from MED to CABG were progressive symptoms or acute decompensation. MED-assigned patients who underwent CABG had lower 5-year mortality than those who received MED only (25% vs 42%; hazard ratio, 0.50; 95% confidence interval, 0.30-0.85; P=0.008).The main reason for crossover from CABG to MED was patient/family decision. Five patients did not undergo their assigned CABG within a year but died before receiving surgery without status change. They were deemed crossover to MED. The CABG-to-MED crossover population had higher 5-year mortality compared with those treated with CABG per-protocol (59% vs 33%; hazard ratio, 2.01; 95% confidence interval, 1.36-2.96; P&lt;0.001). CABG was associated with lower mortality compared with MED in per-protocol and several time-dependent analyses (all P&lt;0.05). CABG reduced mortality in both the per-protocol and crossover STICH patient populations. Crossover from assigned therapy, therefore, diminished the impact of CABG on survival in STICH when analyzed by intention to treat. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.</description><subject>Aged</subject><subject>Comorbidity</subject><subject>Coronary Artery Bypass - mortality</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Coronary Artery Disease - mortality</subject><subject>Coronary Artery Disease - surgery</subject><subject>Coronary Artery Disease - therapy</subject><subject>Cross-Over Studies</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Heart Failure, Systolic - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><issn>1941-3289</issn><issn>1941-3297</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUdFqGzEQFKWhSdP-QhH0pS9OpNPp7kShYIzTGAwB4z6LtW6vVrmTXEnn4HxGv7hKnZokT7vszswOO4R85uyK84pfzxar2e18ulrfTBfLH6t5nhZXjDEu2BtywVXJJ6JQ9dtT36hz8j7GX4xVhZTqHTkvhOSyqOUF-bNwXT-iM0h9R03wMfo9BuodHXxI0Nt0oNZRoAFc6wf7gC2NaWwPj_iAe4hm7CHYB0g2kzJ0lzt0KdJ7m7Y0HmLyvTV0ixAS7cD2Y0CaxajxwTsIB5oXmEtrI0LED-Ssgz7ix6d6SdY38_XsdrK8-76YTZcTUxYqTaSq5UZAXZUdCtY0RjYGjFAFU3JjmpaXjLcblDXnCqGslGKqElBVyOqubcUl-XaU3Y2bAVuTLQfo9S7YIXvSHqx-uXF2q3_6vRZ1weuyygJfngSC_z1iTHqw0WDfg0M_Rs2FLGvFykZm6Ncj9N-DA3anM5zpx1D161DztNDHUDP703OnJ-7_FMVfFiylBw</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Doenst, Torsten</creator><creator>Cleland, John G F</creator><creator>Rouleau, Jean L</creator><creator>She, Lilin</creator><creator>Wos, Stanislaw</creator><creator>Ohman, E Magnus</creator><creator>Krzeminska-Pakula, Maria</creator><creator>Airan, Balram</creator><creator>Jones, Robert H</creator><creator>Siepe, Matthias</creator><creator>Sopko, George</creator><creator>Velazquez, Eric J</creator><creator>Racine, Normand</creator><creator>Gullestad, Lars</creator><creator>Filgueira, Jose Luis</creator><creator>Lee, Kerry L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130501</creationdate><title>Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease</title><author>Doenst, Torsten ; Cleland, John G F ; Rouleau, Jean L ; She, Lilin ; Wos, Stanislaw ; Ohman, E Magnus ; Krzeminska-Pakula, Maria ; Airan, Balram ; Jones, Robert H ; Siepe, Matthias ; Sopko, George ; Velazquez, Eric J ; Racine, Normand ; Gullestad, Lars ; Filgueira, Jose Luis ; Lee, Kerry L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-5975b3a764fe3088c58cac392095bc8d1401dbe57119ea46990963a66e07fdd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Comorbidity</topic><topic>Coronary Artery Bypass - mortality</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Coronary Artery Disease - mortality</topic><topic>Coronary Artery Disease - surgery</topic><topic>Coronary Artery Disease - therapy</topic><topic>Cross-Over Studies</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Heart Failure, Systolic - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Doenst, Torsten</creatorcontrib><creatorcontrib>Cleland, John G F</creatorcontrib><creatorcontrib>Rouleau, Jean L</creatorcontrib><creatorcontrib>She, Lilin</creatorcontrib><creatorcontrib>Wos, Stanislaw</creatorcontrib><creatorcontrib>Ohman, E Magnus</creatorcontrib><creatorcontrib>Krzeminska-Pakula, Maria</creatorcontrib><creatorcontrib>Airan, Balram</creatorcontrib><creatorcontrib>Jones, Robert H</creatorcontrib><creatorcontrib>Siepe, Matthias</creatorcontrib><creatorcontrib>Sopko, George</creatorcontrib><creatorcontrib>Velazquez, Eric J</creatorcontrib><creatorcontrib>Racine, Normand</creatorcontrib><creatorcontrib>Gullestad, Lars</creatorcontrib><creatorcontrib>Filgueira, Jose Luis</creatorcontrib><creatorcontrib>Lee, Kerry L</creatorcontrib><creatorcontrib>STICH Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doenst, Torsten</au><au>Cleland, John G F</au><au>Rouleau, Jean L</au><au>She, Lilin</au><au>Wos, Stanislaw</au><au>Ohman, E Magnus</au><au>Krzeminska-Pakula, Maria</au><au>Airan, Balram</au><au>Jones, Robert H</au><au>Siepe, Matthias</au><au>Sopko, George</au><au>Velazquez, Eric J</au><au>Racine, Normand</au><au>Gullestad, Lars</au><au>Filgueira, Jose Luis</au><au>Lee, Kerry L</au><aucorp>STICH Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease</atitle><jtitle>Circulation. Heart failure</jtitle><addtitle>Circ Heart Fail</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>6</volume><issue>3</issue><spage>443</spage><epage>450</epage><pages>443-450</pages><issn>1941-3289</issn><eissn>1941-3297</eissn><abstract>To assess the influence of therapy crossovers on treatment comparisons and mortality at 5 years in patients with ischemic heart disease and heart failure randomly assigned to medical therapy alone (MED) or to MED and coronary artery bypass graft (CABG) surgery in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. The influence of early crossover (within the first year after randomization) on 5-year mortality was assessed using time-dependent multivariable Cox models. CABG was performed in 65/602 patients (10.8%) assigned to MED, and 55/610 patients (9.0%) assigned to CABG received MED only. Common reasons for crossover from MED to CABG were progressive symptoms or acute decompensation. MED-assigned patients who underwent CABG had lower 5-year mortality than those who received MED only (25% vs 42%; hazard ratio, 0.50; 95% confidence interval, 0.30-0.85; P=0.008).The main reason for crossover from CABG to MED was patient/family decision. Five patients did not undergo their assigned CABG within a year but died before receiving surgery without status change. They were deemed crossover to MED. The CABG-to-MED crossover population had higher 5-year mortality compared with those treated with CABG per-protocol (59% vs 33%; hazard ratio, 2.01; 95% confidence interval, 1.36-2.96; P&lt;0.001). CABG was associated with lower mortality compared with MED in per-protocol and several time-dependent analyses (all P&lt;0.05). CABG reduced mortality in both the per-protocol and crossover STICH patient populations. Crossover from assigned therapy, therefore, diminished the impact of CABG on survival in STICH when analyzed by intention to treat. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.</abstract><cop>United States</cop><pmid>23515275</pmid><doi>10.1161/CIRCHEARTFAILURE.112.000130</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1941-3289
ispartof Circulation. Heart failure, 2013-05, Vol.6 (3), p.443-450
issn 1941-3289
1941-3297
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3721746
source MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals
subjects Aged
Comorbidity
Coronary Artery Bypass - mortality
Coronary Artery Disease - drug therapy
Coronary Artery Disease - mortality
Coronary Artery Disease - surgery
Coronary Artery Disease - therapy
Cross-Over Studies
Disease Progression
Female
Heart Failure, Systolic - mortality
Humans
Male
Middle Aged
title Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A58%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20crossover%20on%20mortality%20in%20a%20randomized%20study%20of%20revascularization%20in%20patients%20with%20systolic%20heart%20failure%20and%20coronary%20artery%20disease&rft.jtitle=Circulation.%20Heart%20failure&rft.au=Doenst,%20Torsten&rft.aucorp=STICH%20Investigators&rft.date=2013-05-01&rft.volume=6&rft.issue=3&rft.spage=443&rft.epage=450&rft.pages=443-450&rft.issn=1941-3289&rft.eissn=1941-3297&rft_id=info:doi/10.1161/CIRCHEARTFAILURE.112.000130&rft_dat=%3Cproquest_pubme%3E1354790485%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1354790485&rft_id=info:pmid/23515275&rfr_iscdi=true